Please login to the form below

Zaltrap

This page shows the latest Zaltrap news and features for those working in and with pharma, biotech and healthcare.

Rise in cancer therapy costs 'unsustainable' says oncologist

Saltz has been a vocal critic of cancer drug pricing for some time, and was one of the architects of MSKCC's decision three years ago not to prescribe Zaltrap ... Zaltrap was also turned down by the UK's National Institute for Health and Care Excellence

Latest news

England's Cancer Drugs Fund: Fixing a broken system

One of these has been Sanofi, whose prostate cancer drug Jevtana (cabazitaxel) and bowel cancer medicine Zaltrap (aflibercept) were deemed too expensive for both the specialist CDF and for NICE. ... Sanofi's Zaltrap (aflibercept):. second line treatment
Pharma condemns Cancer Drugs Fund cuts

Sanofi's Zaltrap is one of several drugs to be delisted from England's Cancer Drugs Fund. ... cancer. In the past 18 months there have been 1, 154 and 707 requests submitted to the CDF for Zaltrap and Jevtana respectively.
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Prostate cancer. Zaltrap (aflibercept). Colorectal cancer. Takeda. Adcetris (brentuximab vedotin). Lymphoma (3 indications). .
Charity demands action on cancer drug prices in UK

Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
England's Cancer Drugs Fund: Naughty or NICE?

Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

The reality of real-world evidence

Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer: Salary TBC

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Senior Account Manager: Competitive Salary Offered

Healthcare Communications Account Directors x 2: Salary TBC

Systematic Reviewer - Oxford: Negotiable

Account Executive/ Senior Account Executive: competitive Salary Offfered

Experienced Medical Writers: Competitive Salary and Benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager / Senior Account Manager: 35, 000-40, 000

Business Director: Competitive Salary Offered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Manager / Account Director: Competative

Editorial Manager - MedComms: DOE

Principal Health Economist - North-West: Negotiable

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Medical (Scientific) Director: £120, 000 benefits

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Account Manager: Negotiable

Account Manager- Healthcare Advertising: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...